The Department of Health (DH) today (July 30) signed a Co-operation Arrangement with the Guangzhou Municipal Market Regulatory Administration, with a view to deepening the exchange and co-operation in the regulation of drugs and medical devices between Guangzhou and the Hong Kong Special Administrative Region (HKSAR), and to jointly promote the development of a healthy Guangdong-Hong Kong-Macao Greater Bay Area (GBA).

     The Vice Mayor of the Guangzhou Municipal Government, Mr Lai Zhihong; Deputy secretary-general of the Guangzhou Municipal Government, Ms Meng Hao; and the Party Secretary of the Guangzhou Municipal Market Regulatory Administration, Mr Zhao Junming, attended the signing ceremony of the Co-operation Arrangement in Guangzhou. The Co-operation Arrangement was signed by the Director of Health, Dr Ronald Lam, and the Director of the Guangzhou Municipal Market Regulatory Administration, Mr Jiang Yingqiao.

     "The Co-operation Arrangement will further strengthen the co-operation in testing of Chinese medicines between the Guangzhou Institute for Drug Control and the Government Chinese Medicines Testing Institute (GCMTI) under the DH of the HKSAR. Together, we will drive the high-quality development of Chinese medicines in the GBA, and jointly contribute to enhance new quality productive forces of the healthcare sector in Guangdong and Hong Kong. The permanent premises of the GCMTI will be completed and commissioned in phases by the end of this year, leveraging its expertise in the research and development of internationally recognised reference standards for Chinese medicines and related products, reinforcing Hong Kong's role as a bridgehead for the internationalisation of Chinese medicines," Dr Lam said.

     Dr Lam visited the Guangzhou Institute for Drug Control on the same day. The institute, established in 1953, is a technical supporting institution under the Guangzhou Municipal Market Regulatory Administration. It was also one of the first four Port Institutes for Drug Control authorised by the National Ministry of Health and one of the five institutions qualified for conducting inspections of first-time imported drugs nationwide. Currently, the Guangzhou Institute for Drug Control possesses technical advantages in testing the level of pesticide residue, heavy metals and harmful elements, residue of mycotoxins and detection of irradiated Chinese medicines by photostimulated luminescence and thin-layer chromatographic identification of Chinese herbal medicine.

     Dr Lam emphasised that the HKSAR Government will establish the "Hong Kong Centre for Medical Products Regulation" (CMPR) by the end of 2026, consolidating regulatory functions for Western and Chinese medicines, as well as medical devices, and enhancing the existing regulatory regime in a holistic manner, in order to fostering growth in the local healthcare and biotechnology industries. The Co-operation Arrangement will strengthen the collaboration of the regulatory networks between the two regions, further promoting the future development of the CMPR.
 
 

Ends/Wednesday, July 30, 2025
Issued at HKT 21:48

NNNN